Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 991

Document Document Title
WO/2022/150603A1
The present disclosure relates to crystalline forms of the compound 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl] benzoic acid hemifumarate, pharmaceutical compositions comprising these compounds and uses thereof to treat ...  
WO/2022/136335A1
Disclosed are crystalline and amorphous forms of linerixibat and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof. Also disclosed is solubility and diss...  
WO/2022/117778A1
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid ...  
WO/2022/108945A1
The present disclosure relates to 1,4-benzothiazepine derivatives and use thereof to treat conditions associated with ryanodine receptors that regulate calcium channel functioning in cells.  
WO/2022/074589A1
The present disclosure provides a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and C...  
WO/2022/074587A1
The present disclosure relates to a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and...  
WO/2022/074588A1
The present disclosure provides a compound having the structure: Formula (I) wherein R1 is –H or –(alkyl); R2 is -(alkyl)-CO2H or -(alkyl)-CO2-(alkyl); R3 is –H or –(alkyl); and X is -Br or -I, or a pharmaceutically acceptable sa...  
WO/2022/029101A1
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid ...  
WO/2021/243461A1
Disclosed is a method of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication thereof, and/or altering the diet of an individual comprising administering DMT, LSD, LSA, or an analog thereof.  
WO/2021/226168A1
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizi...  
WO/2021/208945A1
Disclosed are a benzonitric heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a benzonitric heterocyclic compound represented by formula I, or a pharmaceutically acceptable sal...  
WO/2021/110887A1
The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. Th...  
WO/2021/110883A1
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...  
WO/2021/110884A1
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...  
WO/2021/110886A1
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid ...  
WO/2021/049311A1
Provided is a method for producing a 1,5-benzothiazepin compound, the method being suitable for large, industrial scale production in which less solvent is used, intermediates are not repeatedly purified, and a high-yield of high-purity ...  
WO/2020/161216A1
The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium- dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. T...  
WO/2020/145250A1
[Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.  
WO/2020/027927A1
Dosage forms, formulations, and methods for administering sublingual diltiazem and its use in the treatment of supraventricular arrhythmias, hypertension, coronary artery disease and Raynaud's phenomenon are disclosed.  
WO/2019/234077A1
The invention relates to1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (L...  
WO/2019/185882A1
The invention provides compounds of the formula (1) or salts or tautomers thereof; wherein: Q is SO or SO2; n is 1 or 2; R1 is selected from hydrogen and a non-aromatic C1-6 hydrocarbon group; R2 and R3 are independently selected from hy...  
WO/2019/173761A1
Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as "c-Abl"). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site an...  
WO/2019/172834A1
The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular toa process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and m...  
WO/2019/082910A1
Provided are: a V2 receptor antagonist which has high water solubility and which is particularly suitable for injections; and a medicine containing the V2 receptor antagonist or the like. The present invention is a compound represented b...  
WO/2019/039290A1
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition that has excellent resolution, exposure latitude, and pattern shape properties; and a resist film, a pattern-forming method, a method for producing an electr...  
WO/2018/170275A1
The present invention provides a compound having the structure:, or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorde...  
WO/2018/122606A1
Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6- methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula (I).  
WO/2018/002827A1
Methods for the preparation of the following compound are disclosed. The compound can be incorporated into pharmaceutical formulations, including tablets and such tablets can be used for treating cholestatic liver diseases.  
WO/2017/112988A1
The present invention describes molecules with a hybrid nucleus based on tetrahydroacridine and tianeptine nuclei separated by methyl spacer chains via a coupling reaction, a pharmaceutical composition comprising these molecules, a metho...  
WO/2017/109178A1
A subject of the present invention is the use of a compound having the general formula (I): (I) wherein V, W, X4, X5, X6, X7, X'4, X'5, X'6, X'7, Y, Y', R3, R'3, R4 and R'4 are as defined in any one of claims 1 to 11, for the detection, ...  
WO/2017/055834A1
Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solv...  
WO/2017/049158A1
The present invention provides a compound having the structure of the instant invention or a pharmaceutically acceptable salt or ester thereof, methods of preparing the same, and methods of treating a subject with compounds of the instan...  
WO/2017/048954A1
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a pat...  
WO/2017/044571A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus : The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP...  
WO/2016/151011A1
2-homopiperazine-1-yl-4H-l, 3 -bensothiazine-4-one derivatives of formula (I) are provided. They are useful in the treatment of bacterial infections, in particular tuberculosis, buruli ulcer and leprosy. A process for the preparation of ...  
WO/2016/143650A1
Provided is a compound that exhibits an excellent controlling effect against harmful arthropods. A 3-aminooxalylaminobenzamide compound represented by formula (1) has an excellent controlling effect against harmful arthropods.  
WO/2016/139181A1
The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions com...  
WO/2016/109596A1
Disclosed are novel calcium modulators having formula I: or a pharmaceutically acceptable salt, and including deuterated forms thereof, wherein: Z1, Z2, Z3, Z4 Z5, R1, R1', R2, R3, R3' R4, and R4', are as defined throughout the specifica...  
WO/2016/062848A1
The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1- dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl] oxy}acetyl)amino]-2- phenylethanolyl}glycine (elobixibat).  
WO/2016/064082A2
The present invention relates to a novel aminoalkyl benzothiazepine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition, containing the same as an active ingredient, for preventing or treating const...  
WO/2016/055028A1
The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300....  
WO/2016/020785A1
Methods for preparing the following compound are disclosed.  
WO/2015/195950A1
The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions c...  
WO/2015/155230A1
The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates fr...  
WO/2015/155231A1
The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates fr...  
WO/2015/138791A1
The present invention provides a compound having the structure (I) or a pharmaceutically acceptable salt or ester thereof.  
WO/2015/138220A1
The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the tre...  
WO/2015/109130A1
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2015/017412A1
The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. Th...  
WO/2014/174066A1
The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phen yl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)ami no]-2- phenylethanolyl}glycine (elobixibat), more specifi...  

Matches 1 - 50 out of 991